Clayton, Dubilier & Rice ("CD&R" or the "Firm") today announced that Bill Galvin has been engaged as an Operating Advisor to ...

Resideo Technologies (REZI) has disclosed a new risk, in the Share Price & Shareholder Rights category. The CD&R Stockholder, holding approximately 11% of Resideo Technologies’ total voting power as ...

CVC and Clayton, Dubilier & Rice ("CD&R") today confirmed the completion of the previously announced investment in Epicor, a global provider of industry-specific enterprise software to promote ...

The plan for Public Investment Bank to take a 1% stake in Opella, for about EUR 150M, or $162.98M, came through a tri-party agreement between Sanofi, the French state and CD&R and was approved by ...

P ARIS (Reuters) - Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton ...

PAI is seeking to outbid U.S. rival Clayton Dubilier & Rice (CD&R) for a controlling 50% stake in Opella, the maker of one of France's most-sold painkillers, Doliprane, a source earlier told ...

Sanofi, France's biggest pharmaceutical group, said last week that it was in talks with CD&R for the sale of a 50% ...

The breakthrough came after the investment group provided France with guarantees on maintaining jobs and production in the country following the talks between Sanofi, CD&R and the government ...

The French pharmaceutical group’s board is scheduled to meet to discuss the planned transaction and finalize measures with CD&R to protect jobs and local plants, the people said, asking not to ...

The New York City-based firm, CD&R, is attempting to acquire control of Sanofi subsidiary Opella. Sanofi said it was selling the company as part of its effort to focus on vaccines and innovative ...

Clayton Dubilier & Rice is close to completing a deal to buy control of Sanofi’s (NASDAQ:SNY) consumer health unit after signing social commitments with the French government, Bloomberg News ...